Clarivate is a deeply discounted, subscription-heavy data utility whose upside hinges on selling LS&H to delever and re-rate—before AI and debt costs compress the model.
Overview
Clarivate PLC is presented as a high-conviction restructuring and balance-sheet repair story in global information services and analytics. The company provides data, software, and workflow solutions across Academia & Government, Intellectual Property, and Life Sciences & Healthcare, with widely embedded products like Web of Science, Cortellis, and Derwent supporting more than 12,000 organizations. Management’s “Value Creation Plan” is reshaping the business away from transactional revenue and toward predictable subscriptions: recurring/re-occurring revenue reached ~88% in 2025 (up from ~80% in 2024), with strong retention (~93%). FY2025 revenue declined ~4% to ~$2.46B largely due to divestitures and intentional wind-downs rather than core demand weakness; organic ACV still grew ~1.8%. The central catalyst is the initiated sale process for the LS&H segment (Morgan Stanley advisor), intended to generate substantial proceeds to reduce ~$4.47B of debt and relieve interest burden. With the stock trading at a depressed valuation and an implied FCF yield above 22% on ~$365M 2025 FCF, the report argues upside exists for patient investors—provided the LS&H divestiture executes well and AI-driven product upgrades sustain pricing power.